Involvement of platelets in tumour angiogenesis?

Lancet

Volumn 352, Issue 9142, 1998, Pages 1775-1777

  Pinedo, H M ^a   Verheul, H M W ^a   D'Amato, R J ^b,c   Folkman, J ^b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTICOAGULANT THERAPY; CANCER; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0032576346     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05095-8     Document Type: Note

References (21)

1. 1 Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-68.
2. 2 Verheul HMW, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
3. 3 Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-86.
4. 4 Folkman J. Antiangiogenic therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th edn. Philadelphia: Lipincott-Raven Publishers, 1997: 3075-85.
5. 5 O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997; 88: 277-85.
6. 6 Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82.
7. 7 Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 1996; 14: 2485-93.
8. 8 Dvorak HF. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsch J, Marder VJ, Saltzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Philadelphia: JB Lipincott Company, 1994: 1238-54.
9. 9 Sun NCJ, McAfee M, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Am J Clin Pathol 1979; 71: 10-16.
10. 10 Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Resp J 1996; 9: 1826-30.
11. 11 Monreal M, Fernandez-Llamazares J, Pinol M, et al. Platelet count and survival in patients with colorectal cancer - a preliminary study. Thromb Haemost 1998; 79: 916-18.
12. 12 Colman RW, Marder VJ, Salzman AW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Saltzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Philadelphia: JB Lippincott Company, 1994: 3-18.
13. 13 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
14. 14 Brock TA, Dvorak HF, Senger DR. Tumour secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138: 213-21.
15. 15 Folkman J. Tumour angiogenesis and tissue factor. Nat Med 1996; 2: 67-68.
16. 16 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
17. 17 Fenton JW II. Thrombin functions and antithrombotic intervention. Thromb Haemost 1995; 74: 493-98.
18. 18 Bridges JM, Baldini M. Effect of quinidine and related compounds on uptake and release of serotonin by blood platelets. Nature 1966; 210: 1364-65.
19. 19 Heilmann E, Hynes LA, Friese P, et al. Dog platelets accumulate intracellular fibrinogen as they age. J Cell Physiol 1994; 161: 23-30.
20. 20 Kakkar AK, Williamson RCN. Thromboprophylaxis in malignant disease. Br J Surg 1995; 82: 724-25.
21. 21 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.